272 related articles for article (PubMed ID: 7815807)
1. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.
Bando K; Paradis IL; Komatsu K; Konishi H; Matsushima M; Keena RJ; Hardesty RL; Armitage JM; Griffith BP
J Thorac Cardiovasc Surg; 1995 Jan; 109(1):49-57; discussion 57-9. PubMed ID: 7815807
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.
Kroshus TJ; Kshettry VR; Savik K; John R; Hertz MI; Bolman RM
J Thorac Cardiovasc Surg; 1997 Aug; 114(2):195-202. PubMed ID: 9270635
[TBL] [Abstract][Full Text] [Related]
3. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.
Fiser SM; Tribble CG; Long SM; Kaza AK; Kern JA; Jones DR; Robbins MK; Kron IL
Ann Thorac Surg; 2002 Apr; 73(4):1041-7; discussion 1047-8. PubMed ID: 11996238
[TBL] [Abstract][Full Text] [Related]
4. Causes of death in lung transplant recipients.
Chaparro C; Maurer JR; Chamberlain D; De Hoyos A; Winton T; Westney G; Kesten S
J Heart Lung Transplant; 1994; 13(5):758-66. PubMed ID: 7803415
[TBL] [Abstract][Full Text] [Related]
5. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
Valentine VG; Gupta MR; Walker JE; Seoane L; Bonvillain RW; Lombard GA; Weill D; Dhillon GS
J Heart Lung Transplant; 2009 Feb; 28(2):163-9. PubMed ID: 19201342
[TBL] [Abstract][Full Text] [Related]
6. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management.
Bando K; Paradis IL; Similo S; Konishi H; Komatsu K; Zullo TG; Yousem SA; Close JM; Zeevi A; Duquesnoy RJ
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):4-13; discussion 13-4. PubMed ID: 7609567
[TBL] [Abstract][Full Text] [Related]
7. Lung transplantation for cystic fibrosis: 6-year follow-up.
Quattrucci S; Rolla M; Cimino G; Bertasi S; Cingolani S; Scalercio F; Venuta F; Midulla F
J Cyst Fibros; 2005 May; 4(2):107-14. PubMed ID: 15914093
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development of obliterative bronchiolitis after lung transplantation.
Girgis RE; Tu I; Berry GJ; Reichenspurner H; Valentine VG; Conte JV; Ting A; Johnstone I; Miller J; Robbins RC; Reitz BA; Theodore J
J Heart Lung Transplant; 1996 Dec; 15(12):1200-8. PubMed ID: 8981205
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts.
Tikkanen JM; Kallio EA; Bruggeman CA; Koskinen PK; Lemström KB
Am J Respir Crit Care Med; 2001 Aug; 164(4):672-9. PubMed ID: 11520736
[TBL] [Abstract][Full Text] [Related]
10. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
[TBL] [Abstract][Full Text] [Related]
11. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.
Smith MA; Sundaresan S; Mohanakumar T; Trulock EP; Lynch JP; Phelan DL; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 1998 Nov; 116(5):812-20. PubMed ID: 9806388
[TBL] [Abstract][Full Text] [Related]
12. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.
Manuel O; Kumar D; Moussa G; Chen MH; Pilewski J; McCurry KR; Studer SM; Crespo M; Husain S; Humar A
Transplantation; 2009 Mar; 87(5):719-25. PubMed ID: 19295317
[TBL] [Abstract][Full Text] [Related]
13. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
15. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.
Danziger-Isakov LA; DelaMorena M; Hayashi RJ; Sweet S; Mendeloff E; Schootman M; Huddleston CB; DeBaun MR
Transplantation; 2003 May; 75(9):1538-43. PubMed ID: 12792511
[TBL] [Abstract][Full Text] [Related]
17. Induction immunosuppression for lung transplantation with OKT3.
Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC
Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547
[TBL] [Abstract][Full Text] [Related]
18. Single lung transplantation. Morphological surveillance by transbronchial biopsy.
Foerster A; Bjørtuft O; Geiran O; Rollag H; Leivestad T; Frøysaker T
APMIS; 1993 Jun; 101(6):455-66. PubMed ID: 8395861
[TBL] [Abstract][Full Text] [Related]
19. [Infection in lung transplantation].
Gavaldà J; Román A
Enferm Infecc Microbiol Clin; 2007 Dec; 25(10):639-49; quiz 650. PubMed ID: 18053475
[TBL] [Abstract][Full Text] [Related]
20. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome.
Palmer SM; Davis RD; Hadjiliadis D; Hertz MI; Howell DN; Ward FE; Savik K; Reinsmoen NL
Transplantation; 2002 Sep; 74(6):799-804. PubMed ID: 12364858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
